2022 DONOR IMPACT REPORT

Accelerating a cure for each and every multiple myeloma patient.
LOOKING BACK.

LOOKING FORWARD.

With your continued partnership, we have accelerated new therapies, driven data-based treatment approaches, and provided patients with the resources they need to live longer, better lives.

It gives us great pleasure to present this Donor Impact Report on behalf of all of us at the MMRF. Sharing our accomplishments and successes with you is incredibly gratifying. It not only gives us the chance to express our sincerest thanks to everyone who helps support our important work, but it also provides us with the opportunity to detail the impact your generosity has made in the fight against multiple myeloma.

With your support, we have activated a new strategic plan that will see us through 2026. It is grounded in the MMRF’s vision, core values, and the pillars that motivate our work every day: accelerating the development of novel therapies, driving optimal and more personalized treatment approaches, and empowering patients. Underpinning these pillars is our unwavering commitment to champion diversity, equity, and inclusion.

As you read this report and discover all we have accomplished this past year, I am sure you will feel as optimistic about the future as we do. We have made great progress in 2022, but our job is not yet done. What drives the MMRF every day is a tremendous sense of urgency and commitment to making a significant impact on the lives of patients. As always, we are incredibly hopeful and energized as ever to drive our mission forward with the help and support of our patient and donor community, partners, myeloma researchers, and physicians.

I am confident that together we will achieve our goal—to accelerate a cure for each and every multiple myeloma patient.

Sincerely,

Michael Andreini
President & CEO
Multiple Myeloma Research Foundation
ACCELERATING
THE DEVELOPMENT OF NOVEL THERAPIES

MIF UPDATE
The Myeloma Investment Fund® (MIF) is a self-sustaining venture philanthropy fund that identifies and invests in the most promising biotechnology companies. Its mission is to stimulate the most advanced, cutting-edge research, and attract promising companies to the field of myeloma.

The MIF investment philosophy is simple: We only invest if we see great science that has the potential to be a transformative treatment approach for patients.

This ensures that our approach to making investments is highly focused—identifying companies that exhibit exciting promise. In some cases, that means providing “seed-stage investments”—helping young companies that are developing innovative solutions to unlock the potential for groundbreaking work. This evergreen fund is supported entirely by philanthropy; all financial returns are reinvested back into the fund until there is a cure for each and every patient.

NEW INVESTMENTS
Over the past year, we looked at more than 50 companies before focusing on the following three based on their innovative approaches and potential to develop novel, transformative myeloma therapies. Some of these therapies are still in early-stage development, and our assistance gives them the boost they need to further their innovative research.

We are confident that the dollars earmarked for these companies—made possible by you—could lead to potentially game-changing treatments for patients.

Telo Therapeutics is a young company and we are excited to support the earliest stages of its development plan. Currently, the most promising myeloma treatments are used in combination with other therapies. This approach often improves the efficacy of treatment, but the toxicity is combined as well. Telo’s drug focuses on a proven target in myeloma, but with potentially reduced toxicity compared to the currently approved drug. If proven in clinical trials, this treatment has the potential to be used more broadly and in combination with more treatment options for patients.

KAHR is a clinical-stage biotech company exploring the potential of its lead immunotherapy drug candidate for the treatment of myeloma. This candidate is a novel, bi-specific CD47x4-1BB targeting immunotherapy that aims to activate innate and adaptive immunity to treat solid tumors and blood cancers.

The therapeutic platform is already developed and being evaluated in other cancers; we can help them expand it into the myeloma space and fund a clinical trial.

Luminary Therapeutics is an early clinical-stage cell therapeutics company poised to begin clinical trials with the company’s BAFF CAR-T cell therapy for myeloma patients at University Hospitals Seidman Cancer Center (UH). Luminary’s product is the first CAR-T therapy that targets three distinct antigens present on multiple myeloma tumors. While CAR-T therapy has shown such promise, there still is a need for a second-generation approach to help address existing limitations of current therapies.

With your help, the MIF has committed $15 million to advance myeloma research. But the truest thanks will come from the thousands of people whose lives will be changed as a result of your generosity and vision.

We are excited to have the Myeloma Investment Fund join our syndicate of investors. This vote of confidence helps us advance the clinical development of our lead product candidate, DSP107, which is being tested in multiple clinical studies for the benefit of patients who are nonresponsive or refractory to existing therapies.

– Yaron Pereg, PhD
Chief Executive Officer of KAHR

With your help, the MIF has committed $15 million to advance myeloma research. But the truest thanks will come from the thousands of people whose lives will be changed as a result of your generosity and vision.
We are now able to fully understand the potential of each of these drugs, and the MMRC has helped significantly in moving [many of] these drugs forward.

- Ajay Nooka, MD
  Winship Cancer Institute at Emory University

**CLINICAL UPDATE**

The Multiple Myeloma Research Consortium® (MMRC®) is a network of leading myeloma treatment centers that conduct early-stage clinical trials to evaluate novel treatment strategies for patients. This collaborative research model has conducted more than 80 Phase I and II clinical trials, enrolling thousands of patients to date. The MMRC continues to successfully foster the development of novel therapies and champion rigorous research and clinical trials. Below are three MMRC clinical trials that have the potential to make significant contributions for myeloma treatment.

**Elo-Iber (Relapsed/Refractory)**

Iberdomide (CC-220) is a new and potentially more potent member of a class of medicines known as immunomodulators (IMiDs), which includes Revlimid® (lenalidomide) and Pomalyst® (pomalidomide). This is a phase 1b/2 study that will help determine the optimal dose of iberdomide that can be given to patients— in combination with Empliciti® (elotuzumab) and dexamethasone—that is safe and has the fewest side effects.

This study is currently enrolling patients at Emory University in Atlanta and Mt. Sinai Hospital in New York City, and additional enrollment centers may be added soon.

**ArcellX (Relapsed/Refractory)**

CART-ddBCMA is a CAR-T cell therapy candidate that uses patient T cells that have been genetically modified to recognize and kill myeloma cells. This newer version of CAR-T cell therapy is designed to form a stronger bond to BCMA, a common target for myeloma treatment, and kill myeloma cells more efficiently than previous therapies.

The study will include patients with relapsed or refractory multiple myeloma. Currently, seven MMRC sites are participating, including Hackensack Meridian Health, Simmons Cancer Center at UT Southwestern, Karmanos Cancer Center Institute, Mass General Cancer Center, Atrium Health Cancer Center, and University of Chicago Medicine.

**BeiGene (Relapsed/Refractory)**

This phase I/II study is evaluating how safe and effective a new targeted therapy (BGB-11417) is alone, and in combination with Kyprolis® (carfilzomib) and dexamethasone, in people with relapsed or refractory myeloma. BGB-11417 is a Bcl-2 inhibitor that is potentially effective in myeloma patients with the 11;14 chromosomal translocation, which accounts for about 20% of patients.

Dose escalation will be used to determine the maximum tolerated dose. There will be five expansions to further evaluate safety and efficacy. The participating MMRC sites are City of Hope, Memorial Sloan Kettering Cancer Center, Winship Cancer Institute at Emory University, Ohio State University Comprehensive Cancer Center, and Karmanos Cancer Center Institute.

**ADVANCING TARGETED THERAPIES**

MyDRUG is a groundbreaking clinical trial testing several new treatments for patients with high-risk myeloma. Through the MyDRUG clinical trial, we are researching drugs already FDA-approved for other cancers that are targeting specific genomic mutations also found in myeloma.

Unlike traditional clinical trials, which test one drug or a single combination of drugs, MyDRUG tests the impact of several drugs on different genetic mutations. This not only quickens the speed by which new treatments are evaluated, but also more efficiently matches patients to treatments that are most likely to be beneficial. We are approaching 100 patients enrolled in the MyDRUG clinical trial.

**MyDRUG Highlights from ASH 2022**

MyDRUG was the subject of multiple abstracts presented at the 64th American Society of Hematology (ASH) Annual Meeting. Notable findings include:

- In the MyDRUG study, patients with MAPK pathway mutations were treated with Cotellic® (cobimetinib), a MAPK pathway inhibitor that is FDA-approved for certain types of melanomas. Using single-cell genomic profiling, the MMRF and its research partners detected changes in the tumor cells and in the immune system, providing evidence that the treatment modified both. The findings could lead to a treatment option for patients with these mutations.
- 38 patients who did not have any actionable mutations detected in their bone marrow were treated with Darzalex® (daratumumab) for two cycles and then with Darzalex® in combination with Ninlaro® (ixazomib), Pomalyst®, and dexamethasone (IPD), revealing an overall response rate (ORR) of 92%. Results from the study indicate that this all-oral therapeutic regimen exhibited significant activity and a manageable adverse events profile.
HIGHLIGHTS FROM OUR HEALTH EQUITY SUMMIT

As part of our effort to drive diversity, equity, and inclusion (DEI), and health equity solutions throughout the myeloma and broader rare disease research ecosystem, we led an inaugural Health Equity Summit in Washington, DC, in October 2022.

The Health Equity Summit included stakeholders from across the healthcare sector to identify solutions to making research opportunities more equitable and accessible to those patients who are under-represented in clinical trials. Joining us were physicians from large academic medical centers and community healthcare centers, members of community-based organizations, and representatives from the Food and Drug Administration, the National Cancer Institute, and pharmaceutical companies.

Ultimately, we must hold ourselves and other stakeholders accountable. This effort will go a long way towards advocating for a research population that is more in line with the diversity within the myeloma community, and will help everyone in the long run, getting us to a cure, faster.

IMPLEMENTING HEALTH EQUITY SOLUTIONS

ADAPT CLINICAL TRIAL DESIGN
to broaden eligibility criteria.

EXPAND CLINICAL TRIAL OPERATIONS
to reduce the burden on participants by offering financial assistance, telemedicine, and implicit bias training as part of protocols.

FOCUS ON PATIENT/COMMUNITY EDUCATION AND ENGAGEMENT
to gain early input from patients in the drug development process and inform them with easily understandable materials.

THE FOLLOWING ARE PRIORITY ACTIONS THAT EMERGED FROM THE SUMMIT:
CoMMpass is also a successful example of our initiative to diversify enrollment in clinical trials and better represent patients living with myeloma. Currently, 17% of the patients enrolled in the study are Black, which is consistent with the overall profile of myeloma’s patient population. Recent advancements made possible by these data include a study published by Ben Barwick, PhD, and Larry Boise, PhD, from Winship Cancer Institute at Emory University that identified a possible indicator of high-risk/poor prognosis disease in newly diagnosed myeloma patients. One of the primary contributions of CoMMpass is to help identify markers of high-risk disease. High-risk myeloma can be difficult to predict, and about 20% of patients termed high-risk relapse or pass away within two years of diagnosis. With better prognostic markers at diagnosis, the care team could provide a more personalized course of therapy for these patients from the outset of treatment.

CoMMpass is also a successful example of our initiative to diversify enrollment in clinical trials and better represent patients living with myeloma. Currently, 17% of the patients enrolled in the study are Black, which is consistent with the overall profile of myeloma’s patient population. Recent advancements made possible by these data include a study published by Ben Barwick, PhD, and Larry Boise, PhD, from Winship Cancer Institute at Emory University that identified a possible indicator of high-risk/poor prognosis disease in newly diagnosed myeloma patients. One of the primary contributions of CoMMpass is to help identify markers of high-risk disease. High-risk myeloma can be difficult to predict, and about 20% of patients termed high-risk relapse or pass away within two years of diagnosis. With better prognostic markers at diagnosis, the care team could provide a more personalized course of therapy for these patients from the outset of treatment.

Multiple myeloma is a highly heterogeneous disease, meaning that it is defined by many genomic alterations and can look different in each individual patient. Therefore, a one-size-fits-all treatment approach is not likely effective for every patient.

The MMRF CoMMpass Study was designed to address this issue by providing researchers with as much information as possible about myeloma disease biology to inform future treatment strategies. Through CoMMpass, vast amounts of molecular and clinical data have been collected from more than a thousand patients to create one of the largest myeloma datasets in the public domain. The decade-long study has yielded incredible insights that have transformed our understanding of myeloma, and is changing how myeloma is researched and treated.

Recent advancements made possible by these data include a study published by Ben Barwick, PhD, and Larry Boise, PhD, from Winship Cancer Institute at Emory University that identified a possible indicator of high-risk/poor prognosis disease in newly diagnosed myeloma patients. One of the primary contributions of CoMMpass is to help identify markers of high-risk disease. High-risk myeloma can be difficult to predict, and about 20% of patients termed high-risk relapse or pass away within two years of diagnosis. With better prognostic markers at diagnosis, the care team could provide a more personalized course of therapy for these patients from the outset of treatment.

Immune Atlas

The immune system is a critical factor in myeloma prognosis and treatment because it can detect and destroy abnormal cells, including cancer cells. Therefore, we need to understand how a myeloma patient’s immune system changes during the development of their disease and how it is affected by therapy.

To advance our understanding, we are developing an immune-focused database, called the MMRF Immune Atlas, that utilizes patient samples from our groundbreaking CoMMpass Study. The Immune Atlas is designed to describe the myeloma patient immune system from disease development, through diagnosis, and the treatment journey. The information, collected from hundreds of patients, will be combined with the existing genomic and clinical data from CoMMpass to develop a more comprehensive picture of myeloma disease biology. The insights generated through Immune Atlas will help guide optimal treatment approaches for myeloma patients in the future.

Data from the MMRF helped drive findings from 33 studies featured at ASH, with the CoMMpass Study cited in nine oral abstracts, highlighting the value of the oft-used study by the global myeloma research community. At the conference, we also led a broad overview of immunity in myeloma during a workshop that focused on Immune Atlas. The topics discussed included a review of current findings, opportunities for future data exploration, and ways to improve collaborative analytics.
The MMRF is a trusted organization that has done much to advance treatments for myeloma patients in a short period of time. The CureCloud has huge upside potential benefit for patients and will only succeed with large scale participation.

– Mike W., MMRF CureCloud patient

The MMRF CureCloud® is a first-of-its-kind registry that collects genomic and clinical information to drive more personalized treatments for each and every myeloma patient. The aggregated data is also designed to help researchers discover new targets for myeloma and form hypotheses for clinical trials.

Patients participating in CureCloud have their blood drawn at home by a medical professional. Their blood sample is then sent for sequencing. This sequencing data is combined with the patient’s medical records to provide a better understanding of their disease history. All patient data stored in CureCloud is then anonymized, aggregated, and shared with researchers and medical professionals to help answer clinical questions and inform more personalized treatments for all patients. To date, more than 1,000 patients have enrolled. As more patients enroll, CureCloud will become more powerful, helping to advance research faster. As with all of our research initiatives, we are working to ensure the composition of CureCloud is reflective of the diversity within the myeloma community.

PATIENT REPORTED OUTCOMES

In the fall of 2022, two patient reported outcome (PRO) surveys were administered to CureCloud participants in order to track patient experiences with myeloma therapy over time and across treatments. The Cancer Therapy Satisfaction Questionnaire measured expectations of therapy, feelings about side effects, and satisfaction with cancer therapy. The FACIT-COST survey measured the financial impact related to therapy experienced by myeloma patients. Patients will continue to receive these surveys every six months, and their responses will be linked to the therapy they are receiving so that researchers may understand patients’ quality of life throughout their treatments.

COLLABORATIVE GRANTS

As a leading funder of multiple myeloma research, the MMRF has supported nearly 400 research grants at over 200 institutions worldwide. We support innovative research efforts in the most promising areas of science through several grant-making programs.

MYELOMA ACCELERATOR CHALLENGE PROGRAM GRANTS

In 2022, we announced two $10 million grants supporting new myeloma research initiatives. Each grant will support multicenter translational research projects for three years. Funding these preclinical research programs may ultimately lead to clinical trial deployment for novel myeloma therapies.

Proposals will focus on optimizing treatment for high-risk newly diagnosed multiple myeloma (HR-NDMM) and improving identification and treatment of high-risk smoldering multiple myeloma (HR-SMM). The selected projects will also address racial disparities in the myeloma patient population.

THE 2022 MMRF RESEARCH FELLOW Awardees

Orlando Patino-Escobar, MD
Multiple Myeloma Cell Surface Antigens in NK Cell Inhibition and Exhaustion

Dimitra Karakouni, PhD
Characterizing the T cell Receptor-antigen Dynamics in Multiple Myeloma

Yoshinobu Konishi, MD, PhD
Immune Biomarker of Disease Progression in SMM Defined by Spatial Imaging

Luz Moreno-Rueda, PhD
Development of LAMPS as a Prognostic Biomarker in Multiple Myeloma

Santiago Thibaud, MD
Screening for Pathogenic Germline Variants in Multiple Myeloma

RESEARCH FELLOWS AWARD PROGRAM

One of the most important initiatives of the MMRF is to advance research by attracting young researchers to the field of myeloma. Our Research Fellows Award Program supports investigators at the post-doctorate, medical fellow, or junior faculty levels working under the supervision or guidance of a research mentor at not-for-profit academic institutions in the United States and abroad.

Awardees are provided $150,000 over two years to support their work as they continue to apply their talents to accelerating cures for myeloma, learning more about myeloma’s biology, and identifying potential biomarkers for drug development.

THE MMRF VIRTUAL LAB™

We accelerate scientific advancements for patients when we work together. That is why we invested in a data architecture, analytics, and sharing platform to enable better collaboration. Through our new MMRF Virtual Lab, all the data we generate through a variety of research programs, including CoMMpass and CureCloud, will ultimately be stored and shared with other researchers. By centralizing our data and making it accessible to the broader research community, we can fuel breakthroughs in personalized medicine and improve patient lives faster.

THE 2022 MMRF RESEARCH FELLOW Awardees

Orlando Patino-Escobar, MD
Multiple Myeloma Cell Surface Antigens in NK Cell Inhibition and Exhaustion

Dimitra Karakouni, PhD
Characterizing the T cell Receptor-antigen Dynamics in Multiple Myeloma

Yoshinobu Konishi, MD, PhD
Immune Biomarker of Disease Progression in SMM Defined by Spatial Imaging

Luz Moreno-Rueda, PhD
Development of LAMPS as a Prognostic Biomarker in Multiple Myeloma

Santiago Thibaud, MD
Screening for Pathogenic Germline Variants in Multiple Myeloma

RESEARCH FELLOWS AWARD PROGRAM

One of the most important initiatives of the MMRF is to advance research by attracting young researchers to the field of myeloma. Our Research Fellows Award Program supports investigators at the post-doctorate, medical fellow, or junior faculty levels working under the supervision or guidance of a research mentor at not-for-profit academic institutions in the United States and abroad.

Awardees are provided $150,000 over two years to support their work as they continue to apply their talents to accelerating cures for myeloma, learning more about myeloma’s biology, and identifying potential biomarkers for drug development.

THE MMRF VIRTUAL LAB™

We accelerate scientific advancements for patients when we work together. That is why we invested in a data architecture, analytics, and sharing platform to enable better collaboration. Through our new MMRF Virtual Lab, all the data we generate through a variety of research programs, including CoMMpass and CureCloud, will ultimately be stored and shared with other researchers. By centralizing our data and making it accessible to the broader research community, we can fuel breakthroughs in personalized medicine and improve patient lives faster.
Up until this point, I have not had much success in getting information about multiple myeloma. Then I called the MMRF Patient Navigation Center and spoke with Grace Allison... it was the first time I felt someone cared about me.

– Evelyn Hunley, Myeloma patient

Myeloma is complicated. From understanding the disease, to finding treatment options and clinical trials, the learning curve can seem daunting. That’s why education is central to our mission of empowering patients. Providing high-quality education and support to patients, caregivers, and healthcare providers enables every patient to advocate for their care, achieve better outcomes, and feel more in control.

There are times when patients have questions during their journey with myeloma that only another patient or caregiver can answer. Our Myeloma Mentors program provides patients and caregivers the opportunity to connect with trained mentors. These mentors are fellow patients and caregivers who share personal insights to help inform, activate, empower, and support the multiple myeloma community.

In total, the MMRF’s 11 mentors have assisted in more than 200 cases to date. Ensuring the growth and success of the Myeloma Mentors program is a key focus for the MMRF. Our goal is to ensure that our mentors represent the diversity of the entire myeloma population and range in age, gender, ethnicity, diagnosis, and treatment strategy.

THE SUCCESS OF THESE PROGRAMS can be demonstrated by the numbers of people participating.

<table>
<thead>
<tr>
<th>Total number of registrants from:</th>
<th>Total number of Patient Education Toolkits delivered: 1,456</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educational Programs: 16,359</td>
<td>Patient satisfaction rating from surveys: 4.9/5</td>
</tr>
<tr>
<td>Summits &amp; Expert Sessions: 11,950</td>
<td>Increase in patient confidence/knowledge after attending a MMRF program: 29-32%</td>
</tr>
<tr>
<td>Webinars: 4,409</td>
<td></td>
</tr>
</tbody>
</table>

Our Patient Navigation Center enables myeloma patients and caregivers to connect with patient navigators for support. Patients can connect with a patient navigator via phone, email, or online web form.

In 2022, our Patient Navigators oversaw 3,184 cases, which included 5,314 emails and 4,244 calls.

The MMRF provides patients, caregivers, and healthcare providers with the resources they need to make informed treatment decisions and to optimize their care. These include on-demand information and resources on treatment options, and clinical trials tailored to meet patients exactly where they are on their journey. Our programs include webinars, patient summits, brochures, and Continuing Medical Education-accredited programs for healthcare professionals.
2022 was an important year for the MMRF as we sought to achieve greater diversity, equity, and inclusion (DEI), and health equity solutions in the myeloma community.

Our commitment to DEI is supported by the knowledge that providing equitable access to quality care, treatment, and research opportunities benefits all patients. We work to remove barriers to information, treatment, and care, so that all patients can achieve their best outcomes.

A YEAR OF GREAT STRIDES IN DIVERSITY, EQUITY, AND INCLUSION

Grace Allison, RN, Patient Navigator, and Ola Banjo, Senior Director of Community Engagement and Partnerships, represented the MMRF at the Ochsner Health / National Urban League Louisiana Health Fair in New Orleans.

Our goals focus on ensuring greater inclusivity in research and clinical studies, reducing and ultimately ending disparities through awareness and education, and building an organization and partner network that reflects the diverse community we serve. Some of our achievements this year include:

- Ensuring that our Research Fellows Award Program is attracting a diverse pool of applicants.
- Partnering with the Lazarex Cancer Foundation to provide travel reimbursement to underserved patients enrolled in MMRF-sponsored clinical trials.
- Establishing more community partnerships and continuing our collaboration with Ochsner Health to drive awareness and educate its diverse patient and physician network about myeloma.

While there is still much work to be done, our commitment remains steadfast. We understand that we need to broaden our thinking to achieve real success for all patients.

COMMUNITY OUTREACH & PARTNERSHIPS

Black patients make up 20% of the over 35,000 people estimated to be diagnosed with myeloma annually in the United States. Despite the high incidence of myeloma in the Black community, there are many barriers that prevent Black and other underserved patients from receiving the latest standard-of-care treatment, timely diagnoses, and optimal outcomes when compared to other patient populations.

To break down barriers and improve access to care, it is critical to build relationships in communities that are underserved by the healthcare system. The MMRF is engaging with community leaders and organizations to improve diversity and inclusion among Black and other underserved patients, as well as researchers, through education and medical research opportunities.
when talking about his disease and researching treatments.

He would seek out the latest therapies and advancements, and share his knowledge. He was a person the myeloma patient community would reach out to because of his advocacy for research. He became a resource of knowledge and optimism for friends with the same diagnosis.

And he always maintained a positive outlook. Paul’s doctor for many years was Dr. Robert Schlossman, a very caring and excellent doctor who was at Dana-Farber during most of Paul’s illness. He would tell Paul, ‘Go and live your life.’

Philanthropy became a big part of your lives. How did Team Carter get its start?
Paul felt strongly about supporting the MMRF and the research they were doing. He learned about the MMRF Team for Cures in 2003 and knew that he could create a strong team of supporters from our huge network of family and friends.

My daughters were very much involved with Team Carter. They designed the t-shirts every year. It evolved into a friends, family, and community event. People would donate, participate in the Walk/Run, and then come over to our house for a BBQ, or post-race breakfast.

Team Carter was quite successful.
Team Carter and the MMRF were a very big part of our lives. People would plan their vacations around the MMRF Walk/Run so they could support Team Carter. We would have big showings, 50-100 people at each race. Paul (as the head of Team Carter) won the MMRF award every year for the highest individual fundraiser. In 19 years, we raised over $1 million for the MMRF. Paul always felt that the MMRF and their support of research in creating new drugs for myeloma were the reasons he was alive.

What advice can you give to others facing this situation? What is Paul’s legacy?
We all admired Paul and his ability to live his life no matter what. Good words to live by are what Paul’s brother, Tim, said to him: “There’s more to life than staying alive.”
On behalf of the entire team at the MMRF, I would like to extend a special thanks to everyone who took part in our many fundraising events last year. Whether you walked, ran, organized, cheered from the sidelines, or supported the MMRF in any other way, your contributions fueled progress and inspired hope. Your determination, selflessness, and positive attitude lift up our community and speed progress toward a cure for each and every multiple myeloma patient.

– Mindy Flinn, Vice President of Development
## ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives.

Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.

To learn more, visit TheMMRF.org

### FINANCIALS

<table>
<thead>
<tr>
<th></th>
<th>2022 Financials</th>
<th>2021 Financials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Donors</td>
<td>29,000</td>
<td>22,000</td>
</tr>
<tr>
<td>Total Raised</td>
<td>$45.4M</td>
<td>$42.4M</td>
</tr>
<tr>
<td>Research / Programming</td>
<td>$32.5M</td>
<td>$33.0M</td>
</tr>
</tbody>
</table>

### PROGRAM SPENDING RATIO

- **Research and programming**: 87%
- **Fundraising**: 4%
- **Management**: 9%

To learn more, visit TheMMRF.org
OUR MISSION
To accelerate a cure for each and every multiple myeloma patient.